Proximal Ventures, a new venture capital firm, has successfully raised $27.5 million for its debut fund. The fund, led by former SignalFire investor Sahir Raoof, will focus on investing in startups that integrate artificial intelligence (AI) into drug development processes.
The firm plans to support pre-seed and seed-stage companies, with investments ranging from $500,000 to $1.5 million. Raoof believes AI can automate various stages of drug development, potentially reducing costs and time for pharmaceutical services.
Proximal Ventures has already backed seven startups. One such investment is ChronicleBio, co-founded by former OpenAI executive Fidji Simo, which uses AI to analyse biological and medical data to understand chronic diseases and identify potential treatments.